Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Gilead Sciences agrees a $1.275 billion deal for HCXT-2001, an oral IL-23R inhibitor. Its IBD potential faces major clinical tests.
Pharma & Biotech